All In Biotech

Drug Trial Radar · NCT05859698

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

59

Actual

Start

May 9, 2023

Primary completion

Dec 27, 2024

Study completion Dec 27, 2024

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
May 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar Disorder
  • Major Depressive Disorder
  • Tardive Dyskinesia

Interventions

  • ValbenazineDrug

    Valbenazine capsules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24Time frame: Baseline, Week 24
  2. Change From Baseline in the Sheehan Disability Scale (SDS) Items 1, 2, and 3 Score at Week 24Time frame: Baseline, Week 24
  3. Change From Baseline in the Euro Quality of Life Visual Analogue Scale (EQ-VAS) Score at Week 24Time frame: Baseline, Week 24

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Bryant, Arkansas

  • Neurocrine Clinical Site

    Anaheim, California

  • Neurocrine Clinical Site

    Orange, California

  • Neurocrine Clinical Site

    Torrance, California

  • Neurocrine Clinical Site

    Bonita Springs, Florida

  • Neurocrine Clinical Site

    Miami, Florida

  • Neurocrine Clinical Site

    Miami Lakes, Florida

  • Neurocrine Clinical Site

    Okeechobee, Florida

  • Neurocrine Clinical Site

    Tampa, Florida

  • Neurocrine Clinical Site

    Atlanta, Georgia

  • Neurocrine Clinical Site

    Augusta, Georgia

  • Neurocrine Clinical Site

    Marietta, Georgia

  • Neurocrine Clinical Site

    Lincoln, Nebraska

  • Neurocrine Clinical Site

    Beechwood, Ohio

  • Neurocrine Clinical Site

    Oklahoma City, Oklahoma

  • Neurocrine Clinical Site

    DeSoto, Texas

  • Neurocrine Clinical Site

    El Paso, Texas

  • Neurocrine Clinical Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.